Study identifier:D6876C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily with Placebo in Patients with Non-metastatic Prostate Cancer.
Non-metastatic prostate cancer
Phase 3
No
Bicalutamide, Placebo
Male
1218
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Scandinavian Prostate Cancer Group
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Location
Location
AALBORG, Denmark
Location
ORHUS, Denmark
Location
CHARLOTTENLUND, Denmark
Location
ESBJERG, Denmark
Location
FREDERIKSBERG, Denmark
Location
FREDERIKSSUND, Denmark
Location
GLOSTRUP, Denmark
Location
HERLEV, Denmark
Arms | Assigned Interventions |
---|---|
Placebo Comparator: A | - |
Active Comparator: B | Drug: Bicalutamide 150mg p.o. daily Other Name: Casodex |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.